Cibus’ Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S.
Cibus and its partners Albaugh and RTDC Continue Their Research and Development Collaboration to Enable Commercialization of Cibus’ Clethodim-Tolerant HT-3 Rice Trait
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties announced an agreement affirming its collaboration with RTDC Corporation Limited and Albaugh LLC to provide Clethodim as part of Cibus’ weed management solution for U.S. rice farmers using Cibus’ HT-3 trait. This continued collaboration with Albaugh, a global leader in crop protection, lends complementary market development and herbicide registration expertise and experience to Cibus’ gene editing trait expertise. The collaboration is instrumental to Cibus’ herbicide resistant rice trait commercialization efforts as Cibus also continues its work with its U.S. rice seed customers to bring its Clethodim-tolerant trait to market. These seed and crop protection collaborations are expected to bring together the rice production knowledge and expertise needed to successfully deliver improved rice weed management solutions for U.S. rice growers.
Weed pressure impacts crop yield and quality. Herbicide tolerance traits are an important tool for growers to manage weeds and are a key product area of the multi-billion-dollar trait industry globally. Cibus’ Clethodim tolerant HT-3 trait is an important breakthrough for a novel weed management solution for rice farmers and is one of the two herbicide tolerant traits in rice developed by Cibus that are expected to give rice growers excellent new solutions to manage weeds. It expected to be the first of several stacked weed management traits in rice from Cibus. Cibus currently has four seed partners for this trait: two in the United States and two in South America and is in discussion with other major rice seed companies to advance HT-3 rice in Asia.
Chad W. Shelton, Albaugh’s Group Director for Herbicide Tolerant Crops, stated, “This strategic collaboration and innovative technology has a strong potential to help rice growers in the U.S. and strategic rice markets around the globe keep pace with the most up-to-date herbicide-tolerant crop technologies for assuring high yields and crop quality. Albaugh is excited to be a part of this strategic partnership to develop for rice growers a cropping system powered by the HT-3 trait to help create and deliver performance value.”
Calvin Lu, Vice General Manager of RTDC, commented, “This technology combines the best of Gene Editing technologies from Cibus and superior herbicides provided by Albaugh to help rice growers to increase weed management options with better efficacy against difficult weeds. We are proud to be part of this project combining strengths of three companies in terms of technologies and geographies.”
Norm Sissons, Senior Vice President of Seeds and Traits at Cibus, added, “This partnership with Albaugh completes a critical component of our commercial strategy to bring our Clethodim-tolerant HT-3 trait to market. As we further our collaboration with Albaugh and its professional team of experts with a strong commercial focus enabling getting products to market, we see a promising path to bring Cibus’ novel weed management solution to Rice growers.”
About Cibus
Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus is not a seed company. It is a technology company that uses gene editing to develop and license traits to seed companies in exchange for royalties on seed sales. Cibus' long-term focus is productivity traits for farmers for the major global row crops with large acreage such as canola, rice, and soybean. Cibus is a technology leader in high-throughput gene editing technology that is expected to enable it to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Cibus has developed a current pipeline of five productivity traits including important traits for weed management in Rice, Pod Shatter Reduction, and Sclerotinia (disease) resistance, which are its near-term focus.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the offering and the expected use of the proceeds from the offering. Completion of the offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements made by Cibus’ management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
CIBUS CONTACTS:
INVESTOR RELATIONS
Karen Troeber
ktroeber@cibus.com
858-450-2636
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
Colin Sanford
colin@bioscribe.com
203-918-4347
